What Circadin Treats: Main Uses and Benefits

The primary therapeutic use of this chronobiotic agent is the management of primary insomnia, specifically characterized by poor quality of sleep in older adults. The medication is commonly used to help address these specific symptoms in patients aged 55 years and over.

Circadin is used for managing the core symptoms of primary insomnia, which include chronic difficulties associated with falling asleep (sleep initiation) and staying asleep (sleep maintenance disturbances). This therapeutic focus may help support greater functional stability in sleep patterns, contributing to easing the overall symptom load of non-restorative rest. The medication is relevant for clinical situations involving a fundamental misalignment or disruption of the body's internal clock (circadian rhythm), acting as a supportive agent for conditions involving systemic imbalance.

“This treatment is commonly applied in scenarios where patients experience difficulties with both falling asleep and maintaining restorative sleep throughout the night.”

This approach contributes to supportive therapeutic benefit by aiding in the regulation of sleep timing, which assists with maintaining functional stability and general well-being during symptomatic phases.

---

Quick Fact: Relief for Age-Related Sleep Disruption Circadin is primarily indicated for older adults (aged 55+) with primary insomnia, and supports easing the symptomatic impact on functional stability associated with chronic, poor quality sleep.

Official Eligibility Rules for Circadine

Circadine is officially indicated as a monotherapy for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 years or over. Eligibility is strictly defined by regulatory authorities.

Contraindications and Exclusions

The medicine is contraindicated in patients with a known hypersensitivity to the active substance (melatonin) or any of the excipients. It is also prohibited for patients with rare hereditary problems of galactose intolerance or glucose-galactose malabsorption.

Population Status	Regulatory Classification
Pediatric (Under 18)	Not recommended (Insufficient data)
Hepatic Impairment (Liver)	Not recommended (Decreased clearance)
Autoimmune Diseases	Not recommended (Lack of clinical data)
Pregnancy/Lactation	Not recommended (Safety not established)

Use in patients with renal impairment (kidney disease) requires caution because dedicated studies on the drug's processing in this population have not been performed.

Interactions with other medicines and products

This medicine's interaction profile is primarily defined by the pharmacokinetic effects on its metabolism and its ability to cause pharmacodynamic reinforcement of central nervous system (CNS) effects. Melatonin is primarily metabolized by CYP1A2 enzymes, which dictates many of its documented interactions.

---

Contraindicated and Avoided Combinations

Co-administration with fluvoxamine should be avoided, as this agent is documented to significantly increase melatonin exposure (AUC and Cmax) by inhibiting its metabolism via the CYP1A2 and CYP2C19 pathways. Alcohol should not be taken with this medicine, as regulatory documents state it reduces the overall effectiveness on sleep. Concomitant treatment with benzodiazepine-related hypnotics (e.g., Zolpidem) should be avoided due to the documented potential for enhanced sedative and psychomotor impairing effects.

---

Exposure-Altering Interactions

Substances that inhibit CYP1A2, such as oestrogens (found in contraceptives or HRT), Cimetidine, and Quinolones, may increase melatonin plasma concentrations. Conversely, agents that induce CYP1A2, including Rifampicin and Carbamazepine, along with cigarette smoking, may lead to reduced plasma levels of the medicine. The official label also notes that this product is not recommended for patients with hepatic impairment (liver disease) due to decreased clearance resulting in markedly elevated endogenous melatonin levels.

Central Clock Agonism and Circadian Entrainment

The active ingredient functions as a highly specific agonist at the Melatonin Receptors ( MT1 and MT2) located primarily in the brain’s master timekeeper, the Suprachiasmatic Nucleus (SCN). This targeted molecular interaction modulates the core circadian rhythm pathway. Activation of the MT1 receptor initiates a mechanistic cascade that suppresses neuronal activity in the SCN, generating a physiological signal that influences the transition to the night state, while MT2 receptor activation is central to the synchronization of the internal timing signals (phase-shifting).

---

⏱ Sustained Mechanistic Profile and Physiological Maintenance

The drug is delivered in a prolonged-release formulation, a critical aspect of the mechanism designed to mimic the body’s sustained nocturnal hormone secretion. This sustained agonism ensures the night-state signal remains constant over several hours, contributing to the stabilization of the internal clock and sustaining the regulated signaling of the sleep-wake cycle. This mechanistic profile is necessary for the chronobiotic entrainment to be effective throughout the required duration, modulating the timing and intensity of the circadian rhythm.

How to Use Circadine: Official Administration Guidelines

Circadin is supplied as a 2 mg prolonged-release tablet and is strictly for oral use. The administration guidelines are structured to ensure the active substance is released slowly and steadily over several hours, closely mimicking the body’s natural hormonal signal.

---

Administration Scope

Category	Instruction
Route of administration	Oral use
Dosing schedule	One 2 mg prolonged-release tablet once daily.
Timing in relation to meals	Must be taken after food.
Preparation requirements	Tablets must be swallowed whole; crushing or chewing should not be used.
Age-group administration rules	Indicated for patients aged 55 or over. Use is not recommended in hepatic impairment.
Missed-dose rules	If a dose is forgotten, take it as soon as remembered before going to sleep, or wait until the next scheduled dose. Do not take a double dose.
Special procedural conditions	The dose must be administered 1–2 hours before bedtime. The use is defined as a short-term treatment lasting up to thirteen weeks.

---

Resulting Procedural Structure

The established procedural sequence for administration is:

• Swallow one 2 mg prolonged-release tablet whole.
• Administer the tablet after food to ensure correct absorption kinetics.
• Take the daily dose precisely 1–2 hours before the intended time of sleep.

Connection to the overall use protocol

The method of use consists of a once-daily 2 mg oral dose, taken under specific time and meal conditions. This structure ensures the sustained-release mechanism properly reinforces the body's natural circadian signal throughout the sleep period. The overall regimen is limited to short-term courses, not exceeding thirteen weeks.

Circadine: Recent Clinical Evidence

Clinical trials focusing on Circadine (prolonged-release melatonin 2 mg) have primarily established its efficacy and safety for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 years and over. This age group was selected due to the natural, age-related decline in endogenous melatonin production, which the prolonged-release formulation is designed to mimic throughout the night.

---

Efficacy and Quality of Life

Studies have demonstrated that Circadine significantly improves sleep quality and morning alertness compared to placebo in the indicated population. Key findings include a reduction in sleep latency (the time it takes to fall asleep) and improvements in overall sleep efficiency and duration. Furthermore, the treatment has been associated with a beneficial impact on health-related quality of life and general well-being, as measured by standardized indices. Efficacy has been shown to be maintained for up to 13 weeks of continuous use, the typical maximum duration for the prescribed short-term treatment.

---

Safety and Tolerability

The prolonged-release formulation has shown a favorable safety profile. Common adverse reactions reported in clinical trials were generally mild and included headache, nasopharyngitis, back pain, and joint pain. Importantly, the drug is not associated with the typical risks of conventional hypnotic agents, such as rebound insomnia or withdrawal symptoms upon discontinuation, nor does it appear to lead to tolerance.

Long-term safety data supports the use of the drug for extended periods (up to six to twelve months) in certain studies, which found it to be well-tolerated without suppression of the body's natural melatonin production. It is, however, not recommended for patients with hepatic impairment or autoimmune diseases due to limited clinical data.

Common questions about Circadine (FAQ)

Q: What is the primary purpose of Circadine?

A: Circadine is primarily indicated for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 years and over. It is typically used for a limited period as directed by a healthcare provider.

---

Q: How quickly might Circadine affect sleep quality?

A: In clinical studies, Circadine was observed to promote changes in sleep onset and duration. The full benefit may not be observed immediately and can take several days to weeks of consistent use, as demonstrated in trials of up to 13 weeks.

---

Q: Can Circadine be used for other sleep-related problems?

A: Circadine's authorized indication is specific to primary insomnia in older adults. Use for other sleep disorders, such as jet lag or shift work, is not established under its approved indication. Any off-label use should be discussed with a qualified healthcare professional.

---

Q: Is Circadine associated with daytime drowsiness?

A: Clinical trial data suggested that the incidence of residual or residual effects, such as morning sleepiness, was generally comparable to that experienced with a placebo. However, individual patient responses may vary.

---

Q: Can Circadine be taken with other medications?

A: Circadine may interact with certain other medicines, particularly those that affect the CYP450 liver enzymes, such as fluvoxamine. It is recommended to consult a healthcare provider or pharmacist regarding all current medications to ensure safe use and avoid potential interactions.

---

Q: Is Circadine a habit-forming or controlled substance?

A: Circadine is not classified as a controlled substance and is not considered a traditional hypnotic or benzodiazepine. Studies have not indicated an associated risk of dependency or withdrawal symptoms compared to many other sleep aids.

How to Store and Dispose of Circadin

The storage and disposal of Circadin (melatonin prolonged-release tablets) must strictly follow official regulatory requirements to ensure product stability and environmental safety.

---

Required Storage Conditions

Circadin must be stored at a temperature not exceeding 25°C. The tablets must be kept in the original package in order to protect from light. As a mandatory safety measure, the medicine must be kept out of the sight and reach of children.

Do not use the medicine after the expiry date (EXP) printed on the carton.

---

Official Disposal Instructions

It is mandatory not to throw away any medicines via wastewater or household waste. To ensure proper disposal and help protect the environment, unused or expired Circadin should be returned to a pharmacist or an authorized pharmaceutical collection point.